Mast Therapeutics (MSTX) Reports In-Line Q1 Loss of 6c/Share

Mast Therapeutics (NYSE: MSTX) reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Aon names interim CFO as Edmund Reese exits the firm
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance